May 2nd 2024
The new research will compare eblasakimab to dupilumab and lebrikizumab.
Payers Reveal Most Significant Factors Impacting Biosimilar Coverage Decisions
July 3rd 2023It was found that cancer treatment, pediatric population, and coverage restriction of reference products were revealed as some of the strongest factors associated with biosimilar coverage decisions by US commercial health plans relative to reference products.